Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.
Engelmann R, Jaekel N, Jotschke S, Ludwig-Kraus B, Kraus FB, Kumari N, Schulze S, Hecker M, Zahn C, Al-Ali HK, Junghanss C, Böttcher S.
Engelmann R, et al. Among authors: ludwig kraus b.
Blood Adv. 2023 Jul 25;7(14):3403-3415. doi: 10.1182/bloodadvances.2022009054.
Blood Adv. 2023.
PMID: 36947191
Free PMC article.